

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb60595</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Optimization of the Production of Soluble Recombinant TEV Protease in Two  E. coli Strains </article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Shahriari </surname><given-names>Matineh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Shafiee</surname><given-names>Fatemeh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Moazen</surname><given-names>Fatemeh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Mir Mohammad Sadeghi</surname><given-names>Hamid</given-names></name></contrib><aff>Government College of Pharmacy, Bengaluru, India</aff></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>16</volume>
      <issue>4</issue>
      <fpage>279</fpage>
      <lpage>283</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>2</month>
          <year>2024</year>
        </date>
        <date date-type="accepted">
          <day>25</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Background:&lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; The low solubility of Tobacco Etch Virus (TEV) protease, a functional enzyme that cleaves protein tags without significant modification in its sequence, is one of the most important limitations of this enzyme. In this study, the aim was to increase the solubility of TEV by changing the expression conditions and designing lysis buffer with various solubilizing agents to improve its solubility. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Methods:&lt;/span&gt;&lt;/strong&gt;&lt;em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; &lt;em&gt;Escherichia coli&lt;/em&gt;&lt;/span&gt;&lt;/em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; (&lt;em&gt;E&lt;/em&gt;. &lt;em&gt;coli&lt;/em&gt;) BL21 (DE3) and &lt;em&gt;E. coli&lt;/em&gt; origami harboring wild type TEV-pKR793 and mutant N23F TEV-pKR793 plasmids were used for the expression. Response surface methodology was used to determine the best culture conditions (IPTG concentration, incubation time and incubation temperature) of soluble expression. Furthermore, eight different solubilizing agents were added separately to the lysis buffer to check their effect on the protein solubility. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Results:&lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; The production of soluble N23F in &lt;em&gt;E. coli&lt;/em&gt; BL21 (DE3) was two-folds more than the wild type and the inclusion body formation in the mentioned form was diminished as about 25% in comparison to the wild type. Finally, betaine had the most effects for enhancing the soluble expression of N23F in both host cells. For the wild type, sodium selenite, xylitol, and glycine showed the most effects on soluble production. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Conclusion:&lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; The solubility of the mutant form of TEV protease increased in &lt;em&gt;E. coli&lt;/em&gt; BL21 (DE3) compared to its wild form. Also, using additives such as betaine to the lysis buffer, increased the solubility of N23F in &lt;em&gt;E. coli&lt;/em&gt; BL21 (DE3) and origami strains.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
